Steven E Shoelson

List of Publications by Year in Descending Order

42 papers	19,169 citations	33 h-index	47 g-index
47 ext. papers	20,993 ext. citations	19 avg, IF	6.75 L-index

#	Paper	IF	Citations
42	Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1458-1462	6.7	14
41	Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. *Journal of Clinical Investigation*, **2017**, 127, 83-93	15.9	84
40	The carboxy-terminal region of the TBC1D4 (AS160) RabGAP mediates protein homodimerization. *International Journal of Biological Macromolecules*, **2017**, 103, 965-971	7.9	4
39	Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. *JAMA Cardiology*, **2016**, 1, 413-23	16.2	38
38	Adipose Natural Killer Cells Regulate Adipose Tissue Macrophages to Promote Insulin Resistance in Obesity. *Cell Metabolism*, **2016**, 23, 685-98	24.6	180
37	Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. *Endocrine*, **2015**, 50, 504-7	4	5
36	Insulin receptor activation with transmembrane domain ligands. *Journal of Biological Chemistry*, **2014**, 289, 19769-77	5.4	38
35	Profilin-1 haploinsufficiency protects against obesity-associated glucose intolerance and preserves adipose tissue immune homeostasis. *Diabetes*, **2013**, 62, 3718-26	0.9	19
34	Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). *Diabetes Care*, **2013**, 36, 4132-9	14.6	38
33	Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. *Annals of Internal Medicine* , **2013**, 159, 1-12	8	177
32	Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone. *PLoS ONE*, **2013**, 8, e82847	3.7	18
31	PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. *Nature*, **2012**, 486, 549-53	50.4	762
30	Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 1771-6	9.4	273
29	Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes **2012**, 53, 8424-32		33
28	Type 2 diabetes as an inflammatory disease. *Nature Reviews Immunology*, **2011**, 11, 98-107	36.5	2207
27	Therapeutic approaches to target inflammation in type 2 diabetes. *Clinical Chemistry*, **2011**, 57, 162-7	5.5	90
26	The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. *Annals of Internal Medicine*, **2010**, 152, 346-57	8	287

25	Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. *Nature Medicine*, **2009**, 15, 930-9	50.5	1479
24	Getting away from glucose: fanning the flames of obesity-induced inflammation. *Nature Medicine*, **2009**, 15, 373-4	50.5	81
23	Insulin and Other Antidiabetic Agents **2009**, 1		
22	Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. *Clinical and Translational Science*, **2008**, 1, 36-43	4.9	220
21	Salsalate improves glycemia and inflammatory parameters in obese young adults. *Diabetes Care*, **2008**, 31, 289-94	14.6	285
20	Obesity, inflammation, and insulin resistance. *Gastroenterology*, **2007**, 132, 2169-80	13.3	1240
19	Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. *Diabetes*, **2007**, 56, 499-505	0.9	62
18	Banking on ATM as a new target in metabolic syndrome. *Cell Metabolism*, **2006**, 4, 337-8	24.6	24
17	Inflammation and insulin resistance. *Journal of Clinical Investigation*, **2006**, 116, 1793-801	15.9	2762
16	Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nature Medicine*, **2005**, 11, 183-90	50.5	1729
15	Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. *Journal of Biological Chemistry*, **2004**, 279, 35298-305	5.4	176
14	IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. *Cell*, **2004**, 119, 285-98	56.2	1017
13	SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. *Journal of Biological Chemistry*, **2002**, 277, 42394-8	5.4	652
12	Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. *Journal of Clinical Investigation*, **2002**, 109, 1321-6	15.9	220
11	Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. *Science*, **2001**, 293, 1673-7	33.3	1565
10	Prevention of fat-induced insulin resistance by salicylate. *Journal of Clinical Investigation*, **2001**, 108, 437-46	15.9	519
9	Identification of SOCS-3 as a potential mediator of central leptin resistance. *Molecular Cell*, **1998**, 1, 619-25	27.6	822
8	Crystal structure of the tyrosine phosphatase SHP-2. *Cell*, **1998**, 92, 441-50	56.2	736

7	Conformational changes of the insulin receptor upon insulin binding and activation as monitored by fluorescence spectroscopy. *Biochemistry*, **1997**, 36, 2701-8	3.2	48
6	Structural basis for IL-4 receptor phosphopeptide recognition by the IRS-1 PTB domain. *Nature Structural and Molecular Biology*, **1996**, 3, 388-93	17.6	130
5	Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. *Nature*, **1996**, 379, 277-80	50.4	174
4	T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras. *European Journal of Immunology*, **1995**, 25, 1044-50	6.1	132
3	Structure of the regulatory domains of the Src-family tyrosine kinase Lck. *Nature*, **1994**, 368, 764-9	50.4	253
2	Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. *Nature*, **1993**, 362, 87-91	50.4	501
1	Autophosphorylation within insulin receptor beta-subunits can occur as an intramolecular process. *Biochemistry*, **1991**, 30, 7740-6	3.2	31